Synthetic conjugate peptide Fba-Met6 (MP12) induces complement-mediated resistance against disseminated Candida albicans

The fungal genus Candida includes common commensals of the human mucosal membranes, and most prevalently isolated species, C. albicans , poses a threat candidemia disseminated infection associated with an unacceptably high mortality rate immense $4 billion burden (US) yearly. Nevertheless, demand for vaccine remains wholly unfulfilled increasingly pressing. We developed double-peptide construct that is feasible use in humans intention preventing morbid by targeting epitopes derived from fructose bisphosphate aldolase (Fba) methionine synthase (Met6) which are expressed on cell surface. To test applicability design, we vaccinated mice via intramuscular (IM) route conjugate denoted Fba-Met6 MP12 showed enhanced survival against lethal challenge. Because overall endpoint IgG1 IgG2a antibody titers were robust these mouse subclasses protective functionality, investigated potential Fba Met6 specific antibodies to facilitate well-defined anti- response complement, opsonizes fungi degradation primary effectors. Notably, reductions burdens both abrogated MP12-vaccinated pre-challenge dosed cobra venom factor (CVF), complement depleting factor. Altogether, demonstrated relevant MP12-based protection delineating novel, multivalent targeted proteins surface can enhance natural infection.